U.S. Markets close in 6 hrs 19 mins

Panbela Therapeutics, Inc. (PBLA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4600+0.0200 (+0.58%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4400
Open3.4200
Bid3.1800 x 1800
Ask3.7000 x 1100
Day's Range3.4200 - 3.4600
52 Week Range2.3700 - 10.0000
Volume425
Avg. Volume67,982
Market Cap34.908M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
  • ACCESSWIRE

    50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

    RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event.

  • Panbela Set to Join Russell Microcap® Index
    GlobeNewswire

    Panbela Set to Join Russell Microcap® Index

    MINNEAPOLIS, June 08, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution effective after the US market opens on June 28, according to a preliminary list of additions posted June 4. Membership in the Russell Microcap Index, which remains in place for o

  • Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting
    GlobeNewswire

    Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting

    MINNEAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the presentation of interim clinical data from its Phase 1b combination therapy study of SBP-101, a proprietary polyamine analogue, with gemcitabine and nab-paclitaxel (G+A) in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDA), at the American Society of Clini